News

For all we know about multiple sclerosis (MS) – a chronic disease where a person’s immune system attacks their central nervous system and causes fatigue, bladder issues and pain, among other symptoms – there are still a lot of misconceptions around the condition. Read on to learn what’s fact and what’s fiction when it comes to MS.

When it comes to stroke, it’s crucial to know how to recognize its signs and symptoms so you can access care quickly and preserve brain function. One acronym — BE FAST — can make it easier to identify a stroke, which happens when there’s a blockage to the brain’s blood supply (an ischemic stroke) or a sudden rupture and bleeding in the brain (a hemorrhagic stroke).

BE FAST stands for:

Asthma, a chronic condition that affects the airways in the lungs, can lead to a range of symptoms that interfere with daily life. While most people are familiar with the most common symptoms of asthma such as wheezing or whistling sounds, shortness of breath, chest tightness and frequent coughing, several others are not as widely recognized.

Every February, a very famous football game consumes the general American public. Football is a beloved sport and pastime that celebrates athleticism and teamwork and captures the imaginations of kids who have dreams of going pro. But as The Big Game has grown in size and spectacle over the years, more concern has bubbled up over head injuries, like concussions, in football.

There’s a lot to love about football, but there are also safety factors to consider — as there are with any sport. Here’s what to know about concussions and football.

Like clockwork, two times a year — cold and flu season and allergy season — we get a tingle in our sinuses that can only mean one thing: The snot floodgates are about to open.

For neurologists working with patients with Alzheimer’s disease, the road to actual treatment options has been long and paved with setbacks.

But that is changing for some patients. The Food and Drug Administration recently granted full approval to Leqembi® (lecanemab), the first disease-modifying treatment fully approved for patients in the early stages of Alzheimer’s disease. The development of this new drug offers hope to patients and may have lasting impacts on how physicians approach treatment.